Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1196INDUSTRY 1019NIH 68NETWORK 17OTHER_GOV 16FED 5UNKNOWN 2INDIV 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Cancer 1

Interventions

Proflavine 9Microbial Collagenase 2plerixafor 1pembrolizumab 1pegfilgrastim 1olaparib 1nilotinib 1macimorelin 1keyhole-limpet hemocyanin 1ethyl pyruvate 1compound W 1blinatumomab 1Uracil 1Tegafur 1Surgical Procedures, Operative 1Sodium Chloride 1Sirolimus 1Salicylates 1Peptides 1PM 01183 1Monatide (IMS 3015) 1Mifepristone 1Gemcitabine 1Fluorescein 1Everolimus 1Doxorubicin 1Darbepoetin alfa 1Curettage 1Corlux 1Circumcision, Male 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDIV × Interventional × pembrolizumab × Clear all
NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Aptabio Therapeutics, Inc.

Phase 1 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡